Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 31486842.
- Also identified by DOI 10.1001/jamaoncol.2019.3158 and PMC identifier 6735411.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study examines whether <i>PBRM1</i> alterations are associated with response to immune checkpoint inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.